



August 3, 2020

Web Announcement 2266

Drug Use Review (DUR) Board Approves Changes Effective August 3, 2020

The Nevada Medicaid Drug Use Review (DUR) Board met on January 23, 2020, and voted to adopt the following changes. These changes are effective August 3, 2020.

Drug Class/Program	Changes
Monoclonal Antibody Agents	Updated Food and Drug Administration (FDA) age indication for Nucala®. Added new prior authorization criteria for Nucala® for the treatment of severe asthma and Eosinophilic Granulomatosis with Polyangiitis (EGPA). Added new prior authorization criteria for Dupixent®.
Multiple Sclerosis Agents	Added new prior authorization criteria for medications used for the treatment of Multiple Sclerosis (MS).
Functional Gastrointestinal Disorder Agents	Added new prior authorization criteria for Zelnorm®.
Narcolepsy Agents	Added new prior authorization criteria for Sunosi®.
Anticonvulsants	Added new prior authorization criteria for Nayzilam®.

Prior authorization forms may be found on the Pharmacy Forms webpage at:

<https://www.medicaid.nv.gov/providers/rx/rxforms.aspx>